Ocugen Inc (NASDAQ:OCGN) — Market Cap & Net Worth
Market Cap & Net Worth: Ocugen Inc (OCGN)
Ocugen Inc (NASDAQ:OCGN) has a market capitalization of $358.83 Million ($358.83 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14031 globally and #3371 in its home market, demonstrating a -19.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ocugen Inc's stock price $1.06 by its total outstanding shares 338521856 (338.52 Million). Also see Ocugen Inc assets under control for a full breakdown of the balance sheet.
Ocugen Inc Market Cap History: 2015 to 2026
Ocugen Inc's market capitalization history from 2015 to 2026. Data shows change from $71.09 Billion to $358.83 Million (-39.79% CAGR). Also see OCGN cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Ocugen Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.01% | #382 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #1373 of 3165 |
Weight: Ocugen Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ocugen Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ocugen Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Ocugen Inc (OCGN) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
103.56x
Ocugen Inc's market cap is 103.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $176.03 Million | $42.62K | -$20.24 Million | 4130.25x | N/A |
| 2020 | $619.49 Million | $43.00K | -$21.82 Million | 14406.86x | N/A |
| 2021 | $1.54 Billion | $22.92K | -$58.37 Million | 67202.20x | N/A |
| 2022 | $440.08 Million | $2.49 Million | -$77.83 Million | 176.88x | N/A |
| 2023 | $194.65 Million | $6.04 Million | -$63.08 Million | 32.25x | N/A |
| 2024 | $272.51 Million | $4.05 Million | -$54.05 Million | 67.20x | N/A |
| 2025 | $457.00 Million | $4.41 Million | -$67.85 Million | 103.56x | N/A |
Competitor Companies of OCGN by Market Capitalization
Companies near Ocugen Inc in the global market cap rankings as of September 17, 2026. Review OCGN goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Ocugen Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Ocugen Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Ocugen Inc's market cap moved from $71.09 Billion to $ 358.83 Million, with a yearly change of -39.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $358.83 Million | -21.48% |
| 2025 | $457.00 Million | +67.70% |
| 2024 | $272.51 Million | +40.00% |
| 2023 | $194.65 Million | -55.77% |
| 2022 | $440.08 Million | -71.43% |
| 2021 | $1.54 Billion | +148.63% |
| 2020 | $619.49 Million | +251.92% |
| 2019 | $176.03 Million | -90.15% |
| 2018 | $1.79 Billion | -95.71% |
| 2017 | $41.64 Billion | +22.75% |
| 2016 | $33.92 Billion | -52.29% |
| 2015 | $71.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Ocugen Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $358.83 Million USD |
| MoneyControl | $358.83 Million USD |
| MarketWatch | $358.83 Million USD |
| marketcap.company | $358.83 Million USD |
| Reuters | $358.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase… Read more